The exclusivity modelling layer
Model every scenario before BD locks the term sheet.
Change #7 of 10 — BD / RA / Commercial
The 8+2 years you modelled for? That's not the default anymore.
The directive replaces flat 8+2+1 exclusivity with a tiered system. Baseline is shorter. Extensions are real — but conditional on EU-wide launch, unmet medical need, and access commitments. Every pipeline NPV model needs rebuilding.
Art. 81–84 — Data Exclusivity
8+2 → 6+2Guaranteed years drop. The rest is earned.
Current — guaranteed 8 + 2
Data · 8y
Market · 2y
New — guaranteed 6 + 2, then conditional
Base · 6y
Mkt · 2y
earn-back
Earn back by+ years
Launch across the EU-27+2
Addresses an unmet need+1
Comparative clinical trials+0.5
The automatic baseline falls from 8 to 6 years. To get back toward the old protection you now have to earn it — by launching EU-wide, meeting unmet need, and more.
The commercial impact
Two fewer guaranteed years — unless you earn them back
The shift from guaranteed 10-year exclusivity to conditional 8-year baseline fundamentally changes NPV for every pipeline product.
6+2
New baseline: 6 years data exclusivity plus 2 years market exclusivity — down from 8+2
SourceEU Pharmaceutical Directive 2026
+2yr
Extension for EU-wide launch in all Member States within 2 years of first MA grant
SourceEU Pharmaceutical Directive 2026
Up to +3
Additional conditional years: unmet need, comparative trial, new post-approval indication
SourceEU Pharmaceutical Directive 2026
What's actually changing
From guaranteed protection to earned exclusivity
The old framework rewarded innovation with fixed exclusivity. The new framework rewards EU-wide access, unmet need focus, and comparative evidence.
Workbench
+ New TaskQuick Tasks/Data exclusivity — current vs new directive
Our BD team modelled this deal on 8+2 years of exclusivity. The new directive changes the baseline to 6+2. How bad is it?
RegIntel12:39
117.00s207 sources94% confidence2 warnings
2 warnings
Here's the obligation delta for Data exclusivity. The new EU Pharmaceutical Directive replaces Directive 2001/83/EC[1][2] — below is what changes, row by row.
Current vs. new directive4 rows
Change area
Current — 2001/83/EC
New directive — from ~mid-2028
Baseline exclusivity
Current
8 years data + 2 years market = 10 years total. Granted automatically at first MA with no launch conditions.
Launch timing
Current
No linkage between launch sequencing and exclusivity. Selective EU launch retained full protection.
New directive
+2 years data exclusivity if launched in all EU Member States within 2 years of first MA. Launch sequencing is now a regulatory strategy decision.[5]
Clinical development incentives
Current
+1 year for new indication post-approval. No extension for comparative trials or unmet need beyond orphan.
New directive
Three conditional +1 year extensions: unmet medical need, comparative clinical trial vs active comparator, significant new post-approval indication.[6]
⚠Dates reflect the political agreement text; final deadlines depend on entry into force and the transition period for each obligation.
Synthesised from 13 citations across 207 regulatory sources.
Book a 15-minute live walkthrough of the Workbench
Where the commercial impact hits
The missing layer
NPV models, in-licensing valuations, and launch sequencing plans all need rebuilding. Most organisations aren't equipped at portfolio scale.
FI
Financial models (Excel, Anaplan)
The NPV tools
LA
Launch planning teams
The sequencing owners
How Regunaut solves it
Five steps. Full exclusivity under the new framework.
Each step maps exclusivity management — from modelling portfolio position through earning every extension allowed.
Three scenarios per product: base (8 years), expected (10 with EU launch), upside (up to 13 with all extensions) — built from actual development plans, not generic assumptions.
- Per-product three-scenario exclusivity model
- Extension eligibility assessment per criterion
- NPV impact calculator vs 10-year baseline
- Portfolio exclusivity risk heat map
Commercial evidence
The exclusivity change is reshaping pipeline valuations
Companies that quantify their new exclusivity position and plan to earn maximum extensions will have a material advantage in pipeline value and deal negotiations.
€280M
Estimated NPV impact of 2-year exclusivity reduction on a mid-size specialty product with €400M peak EU sales
Regunaut exclusivity NPV model, 2025
67%
Of EU launches 2022–2023 available in fewer than 15 of 27 Member States within 2 years — missing +2-year extension threshold
EFPIA patient W.A.I.T. indicator, 2023
3×
Increase in EU in-licensing discussions citing exclusivity changes as material deal term concern in Q1 2026
Pharma Licensing Group survey, Q1 2026
“The link between launch sequencing and exclusivity period alone will reshape how companies prioritise EU market entry. The 10-year assumption underpinning pipeline valuations is no longer valid.”
Common questions
What teams are asking about the new exclusivity framework
Rebuild your pipeline exclusivity models before the next board review
Your NPV assumptions have changed. Regunaut tells you by how much — and what to do to earn the full period back.
Model your exclusivity portfolio
Per-product scenario report: baseline, expected and upside with extension criteria mapped to your development plan.
Model my exclusivityPrepare a BD briefing pack
Deal-ready exclusivity model for a specific in-licensing or out-licensing asset.
Book BD strategy session